RECRUITING Not applicable ClinicalTrials.gov

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Sponsor: University of Chicago • ClinicalTrials.gov ID: NCT05710380

Registry updated: 2026-09-01

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.

Interventions

Risk Map Decision Support System (DSS). (Other)
The Risk Map DSS tool is an image analysis software that automatically interprets images of the prostate that were captured using an MR (magnetic resonance) scanner (an imaging technique that uses scanners to take pictures of the body). This tool can potentially identify additional areas of cancer in your prostate that may have otherwise been missed.
Magnetic Resonance Imaging (MRI) (Radiation)
A medical imaging test that uses a large machine/scanner to take images of the body and internal organs and structures.
Magnetic Resonance Imaging (MRI) Guided Biopsy (Procedure)
A removal of tumor tissue from the body based on images of the prostate provided by a previous magnetic resonance imaging (MRI) test. Up to 2 biopsies on trial.

Eligibility criteria

Inclusion Criteria: * Patients with known or suspected prostate cancer who have been referred for a diagnostic magnetic resonance imaging (MRI) exam of the prostate, to be followed by an MRI-guided fusion biopsy of the prostate. * Voluntary written informed consent before the MRI examination. Exclusion Criteria: * Subjects incapable of giving informed written consent. * Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher; * Subjects with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders. * Prisoners. * Minor children (under the age of 18 years old). * Patients with previous treatments (surgery, radiation, focal ablation, hormone or other chemotherapy) for prostate cancer.

Conditions

Prostate Cancer Prostate Adenocarcinoma Prostate Neoplasm

Locations

University of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois, United States
Oregon Health & Science University — Portland, Oregon, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment